A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis
- 30 June 2009
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 217 (2) , 258-268
- https://doi.org/10.1016/j.expneurol.2009.02.017
Abstract
No abstract availableKeywords
Funding Information
- Passano Foundation
- Muscular Dystrophy Association
This publication has 33 references indexed in Scilit:
- Skeletal Muscle Is a Primary Target of SOD1G93A-Mediated ToxicityCell Metabolism, 2008
- Donepezil for Alzheimer’s diseaseExpert Review of Neurotherapeutics, 2007
- A randomized controlled trial of resistance exercise in individuals with ALSNeurology, 2007
- Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trialThe Lancet Neurology, 2006
- Functional improvement of dystrophic muscle by myostatin blockadeNature, 2002
- The value of muscle exercise in patients with amyotrophic lateral sclerosisJournal of the Neurological Sciences, 2001
- Direct binding of Smad3 and Smad4 to critical TGFbeta -inducible elements in the promoter of human plasminogen activator inhibitor-type 1geneThe EMBO Journal, 1998
- RiluzoleDrugs, 1996
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- The histographic analysis of human muscle biopsies with regard to fiber typesNeurology, 1969